Lytix Biopharma AS Sustainability Reports
Lytix Biopharma ASA is a clinical-stage biotechnology company that develops novel cancer immunotherapies. Its technology platform utilizes host-defense peptide-derived molecules to target and kill cancer cells while stimulating the patient's immune system.
Sector: Professional & technical services
Country: Norway
Exchange: Oslo Børs
LEI: 549300NXMIMRSBCDZO71
FIGI: BBG005486GS4
5 reports from 2020 to 2025
